← Leaderboards
Steven F Dowdy
University Of California San Diego
$4,624,166
Attributed
$4,624,166
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $992K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,624,166 · 11
By mechanism
R21$3,028,127 · 8
R01$1,593,180 · 2
P41$2,859 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- William R. Freeman$11,346,515
- Mark P Kamps$4,976,679
- Pamela L Mellon$36,611,301
Others in their field
Top investigators on “Small Interfering Rna”
- Randall J Bateman · Washington University$62,939,456
- Thomas William Geisbert · Boston University Medical Campus$30,074,519
- Judy Lieberman · Boston Children'S Hospital$24,680,725
- Michael Welch · Washington University$18,835,712
- Anastasia Khvorova · Rxi Pharmaceuticals Corporation$17,475,922
- Michael P Czech · Univ Of Massachusetts Med Sch Worcester$15,688,365
Research focus
Small Interfering RnaRna InterferenceResponseChargeAlzheimer&AposMouse ModelCellsIn VivoPharmaceutical PreparationsGeneticPre-ClinicalGrowthNext GenerationInorganic PhosphateOncogenesMonoclonal AntibodiesOverexpressionVertebral ColumnProdrugsAffectMutationOncogenicGenomeCancer Etiology
Grant awards (20)
Treating Alzheimer's Disease with PMO RNA Therapeutics$238,500
R21 · FY2025 · NS · contact PI
Precision Genetic RNAi Medicines to Treat Metastatic Triple-Negative Breast Cancer (TNBC)$180,970
R21 · FY2023 · CA · contact PI
Precision Genetic RNAi Medicines to Treat Metastatic Triple-Negative Breast Cancer (TNBC)$221,595
R21 · FY2022 · CA · contact PI
Development of Next-Generation RNAi Therapeutics to Treat Alzheimer's Disease$415,156
R21 · FY2020 · NS · contact PI
Development of Next-Generation Precision Medicine RNAi Therapeutics to Treat AML$405,557
R21 · FY2020 · CA · contact PI
Development of Antibody-RNAi Conjugates (ARCs) to Treat Lung Cancer$171,281
R21 · FY2020 · CA · contact PI
Regulation of RNA metabolism and cell growth control by SR protein kinases$348,750
R01 · FY2019 · GM · contact PI
Development of Antibody-RNAi Conjugates (ARCs) to Treat Lung Cancer$205,157
R21 · FY2019 · CA · contact PI
Treating Adenovirus Conjunctivitis with Next-Gen siRNN RNAi Prodrugs$208,090
R21 · FY2018 · EY · contact PI
Treating Adenovirus Conjunctivitis with Next-Gen siRNN RNAi Prodrugs$245,201
R21 · FY2017 · EY · contact PI
Treating Prostate Cancer with RNAi Prodrugs$168,563
R21 · FY2016 · CA · contact PI
Treating Prostate Cancer with RNAi Prodrugs$202,275
R21 · FY2015 · CA · contact PI
Novel Cell Cycle Therapeutic Targets in Pancreatic Cancer$163,507
R21 · FY2014 · CA · contact PI
Novel Cell Cycle Therapeutic Targets in Pancreatic Cancer$202,275
R21 · FY2013 · CA · contact PI
ROLE OF CYTOPLASMIC P27KIP1 IN CELL MOTILITY AND METASTASIS$2,859
P41 · FY2006 · RR · contact PI
Transduction of Tumor Suppressor Proteins into Gliomas$248,886
R01 · FY2005 · CA
Transduction of Tumor Suppressor Proteins into Gliomas$248,886
R01 · FY2004 · CA
Transduction of Tumor Suppressor Proteins into Gliomas$248,886
R01 · FY2003 · CA
Transduction of Tumor Suppressor Proteins into Gliomas$248,886
R01 · FY2002 · CA
Transduction of Tumor Suppressor Proteins into Gliomas$248,886
R01 · FY2001 · CA